Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franck Bonnetain

Showing results (131-140 of 161) with videos related to

Pageof 17
Sort By:
Cancer Medicine|July 18, 2019
Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trialEmilie Charton, Jean-Baptiste Bachet, Pascal Hammel, et al.
The Lancet. Gastroenterology & Hepatology|April 12, 2017
Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trialJean-Baptiste Bachet, Pascal Hammel, Jérôme Desramé, et al.
The European Respiratory Journal|June 25, 2016
Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapyFrédéric Fiteni, Amélie Anota, Franck Bonnetain, et al.
Cancer Chemotherapy and Pharmacology|May 15, 2014
Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancerMarine Jary, Francois Ghiringhelli, Marion Jacquin, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 1, 2014
Statistical challenges of quality of life and cancer: new avenues for future researchLaurent Boyer, Karine Baumstarck, Pierre Michel, et al.
Clinics and Research in Hepatology and Gastroenterology|April 30, 2021
Chemotherapy use in end-of-life digestive cancer patients: a retrospective AGEO observational studyAlexandra Lapeyre-Prost, Geraldine Perkins, Marie Vallee, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2013
S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinomaJean-Baptiste Bachet, Raphael Maréchal, Pieter Demetter, et al.
Bulletin Du Cancer|January 23, 2015
[The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB]Monia Ezzalfani, Audrey Dugué, Caroline Mollevi, et al.
Cancer Medicine|January 26, 2016
PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancerBenoist Chibaudel, Frédérique Maindrault-Gœbel, Jean-Baptiste Bachet, et al.
Cancer Medicine|February 17, 2015
Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 studyBenoist Chibaudel, Roger Lacave, Marine Lefevre, et al.
Pageof 17

Showing results (131-140 of 161) with videos related to

Sort By:
Pageof 17
Cancer Medicine|July 18, 2019
Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trialEmilie Charton, Jean-Baptiste Bachet, Pascal Hammel, et al.
The Lancet. Gastroenterology & Hepatology|April 12, 2017
Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trialJean-Baptiste Bachet, Pascal Hammel, Jérôme Desramé, et al.
The European Respiratory Journal|June 25, 2016
Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapyFrédéric Fiteni, Amélie Anota, Franck Bonnetain, et al.
Cancer Chemotherapy and Pharmacology|May 15, 2014
Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancerMarine Jary, Francois Ghiringhelli, Marion Jacquin, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 1, 2014
Statistical challenges of quality of life and cancer: new avenues for future researchLaurent Boyer, Karine Baumstarck, Pierre Michel, et al.
Clinics and Research in Hepatology and Gastroenterology|April 30, 2021
Chemotherapy use in end-of-life digestive cancer patients: a retrospective AGEO observational studyAlexandra Lapeyre-Prost, Geraldine Perkins, Marie Vallee, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2013
S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinomaJean-Baptiste Bachet, Raphael Maréchal, Pieter Demetter, et al.
Bulletin Du Cancer|January 23, 2015
[The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB]Monia Ezzalfani, Audrey Dugué, Caroline Mollevi, et al.
Cancer Medicine|January 26, 2016
PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancerBenoist Chibaudel, Frédérique Maindrault-Gœbel, Jean-Baptiste Bachet, et al.
Cancer Medicine|February 17, 2015
Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 studyBenoist Chibaudel, Roger Lacave, Marine Lefevre, et al.
Pageof 17